Section 6

510(k) Summary
X-Port duo™ Implanted Port with 9.5 Fr. Polyurethane Catheter

510(k) Summary of Safety and Effectiveness Information
21CFR 807.92

6.1 Submitter Information
Submitter Name: Bard Access Systems, Inc. (BAS)
[Subsidiary of C. R. Bard, Inc.]
Address: 5425 W. Amelia Earhart Drive
Salt Lake City, UT 84116
Telephone Number: (801) 595-0700, Ext. 5470
Fax Number: (801) 595-5425
Contact Person: Angela Brady
Date of Preparation: 24 December 2003

6.2 Device Name
Device Name: Plastic Dual Port
Trade Name: X-Port duo Port
Catheter: 9.5 Fr. open ended dual lumen polyurethane
Common/Usual Name: Plastic Subcutaneous Port & Catheter
Classification Name: 80LJT - Port & Catheter, Implanted, Subcutaneous, Intravascular
21 CFR 880.5965 - Subcutaneous, Implanted, Intravascular Infusion Port and Catheter, Class II
Classification Panel: General Hospital

6.3 Predicate Device Name
Device Name: Plastic Dual Port
Trade Name: X-Port duo Port
Catheter: 10 Fr. open ended dual lumen silicone
Common/Usual Name: Plastic Subcutaneous Port & Catheter
Classification Name: 80LJT - Port & Catheter, Implanted, Subcutaneous, Intravascular
21 CFR 880.5965 - Subcutaneous, Implanted, Intravascular Infusion Port and Catheter, Class II
Premarket Notification: K032044, concurrence date – 10 July 2003

6.4 Device Description
Principles of Operation
There are no new operating principles. The X-Port duo™ port with 9.5 Fr. polyurethane catheter has the same basic, fundamental scientific technology as the predicate X-Port duo™ port. Access to the port is made percutaneously with a non-coring needle that enters the port reservoir via the silicone rubber septum. The access path to the vascular system is provided through a catheter attached to the base of the port. The port system serves as a conduit for fluids into, and out of, the central venous system.
X-Port duo™ Implanted Port with 9.5 Fr. Polyurethane Catheter
Premarket Notification [510(k)]

Port Body
- The port body consists of a lightweight plastic base and top with a tapered nose and large silicone septa.

Catheter
- The catheter is a 9.5 Fr. dual lumen polyurethane catheter.

6.5 Intended Use

The X-Port duo™ Implanted Port is a totally implantable vascular access device designed to provide long term repeated access to the vascular system.

This is the identical intended use for the predicate device.

6.6 Summary of Technological Characteristics in Relation to the Predicate Device

The primary difference between predicate and subject device is the catheter material. The predicate port catheter is composed of silicone and the subject port catheter is composed of polyurethane. The basic fundamental scientific technology has not changed.

6.7 Nonclinical Performance Testing

The appropriate design verification tests were performed in accordance with Guidance on 510(k) Submission for Implanted Infusion Ports, dated October 1990 and other applicable guidance documents and standards. Design validation was also performed to meet the recommendations of the FDA guidance document, Design Control Guidance for Medical Device Manufacturers, dated March 11, 1997.

Performance data gathered in design verification and validation testing demonstrated that the X-Port duo™ port with 9.5 Fr. polyurethane catheter is substantially equivalent to the predicate X-Port duo™ port with 10 Fr. silicone catheter and/or met predetermined acceptance criteria, and the risks associated with use of the new device were found acceptable when evaluated by FMEA.

6.8 Clinical Performance Testing

Clinical performance testing was not required.

6.9 Conclusion

Based on FDA’s decision tree, the X-Port duo™ port with 9.5 Fr. polyurethane catheter is substantially equivalent to the predicate device X-Port duo™ port with 10 Fr. silicone catheter, K032044, cleared 10 July 2003.
Dear Ms. Brady:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4618. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Chiu Lin, Ph.D.
Director
Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure
INDICATION(S) FOR USE STATEMENT*

The BardPort®, SlimPort™ and X-Port™ Implanted Ports are indicated for patient therapies requiring repeated access to the vascular system. The port system can be used for infusion of medications, I.V. fluids, parenteral nutrition solutions, blood products and for the withdrawal of blood samples.

Signature of 510(k) Submitter:  
Printed Name of Submitter: Angela Brady  
Engineer – Regulatory Affairs  
Date:  

*Suggested language and format to meet the requirements of sections 513(i) of the Federal Food, Drug, and Cosmetic Act, as amended, and sections 807.92(a)(5) and 801.4 of the Code of Federal Regulations, Title 21.

Concurrence of Office of Device Evaluation

510(k) Number: K034065

Division Sign-Off:  
Office of Device Evaluation

Prescription Use: ✓ - OR - Over-The-Counter Use:  

(Division Sign-Off)  
Division of Anesthesiology, General Hospital, Infection Control, Dental Devices  
510(k) Number: K034065